Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa study of TG6002 (VV TK-RR-FCU1) administered by intravenous (IV) infusions in combination with oral flucytosine (5-FC) in patients with advanced gastro-intestinal (GI) tumors

Trial Profile

A Phase I/IIa study of TG6002 (VV TK-RR-FCU1) administered by intravenous (IV) infusions in combination with oral flucytosine (5-FC) in patients with advanced gastro-intestinal (GI) tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TG 6002 (Primary) ; Flucytosine
  • Indications Carcinoma; Colorectal cancer; Gastrointestinal cancer; Liver metastases
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Transgene
  • Most Recent Events

    • 18 Sep 2019 According to an Transgene media release, first clinical safety results are expected at the end of the year 2019.
    • 07 Aug 2019 According to an Transgene media release, the company expects to announce the first clinical data with TG6002 in patients with colorectal cancer later in 2019.
    • 31 Jul 2019 Planned number of patients changed from 59 to 65.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top